Bay Colony Advisors’s Intellia Therapeutics NTLA Stock Holding History

Bay Colony Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,188	Closed	-$212K	–	371
2023 Q2	$212K	Sell	5,188 -712	-12%	-$28.9K	0.05%	310
2023 Q1	$213K	Sell	5,900 -100	-2%	-$3.92K	0.06%	294
2022 Q4	$209K	Hold	6,000	–	–	0.06%	322
2022 Q3	$336K	Buy	6,000 +350	+6%	+$21.7K	0.1%	199
2022 Q2	$366K	Buy	5,650 +450	+9%	+$22.9K	0.09%	207
2022 Q1	$378K	Buy	5,200 +250	+5%	+$21.2K	0.09%	221
2021 Q4	$585K	Buy	4,950 +400	+9%	+$50.1K	0.17%	151
2021 Q3	$610K	Hold	4,550	–	–	0.2%	140
2021 Q2	$737K	Hold	4,550	–	–	0.25%	119
2021 Q1	$365K	Hold	4,550	–	–	0.14%	190
2020 Q4	$248K	Buy	+4,550	New	+$165K	0.13%	225

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bay Colony Advisors's NTLA Position: Q3 2023 in Review

Bay Colony Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2023, closing a stake of 5,188 shares — an estimated $212K sold.

Bay Colony Advisors first reported a position in NTLA in Q4 2020 and held it in 11 quarters. The position peaked at $737K in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2023.

Bay Colony Advisors reported no remaining Intellia Therapeutics position as of Q3 2023 after selling out during the quarter.
Bay Colony Advisors sold 5,188 Intellia Therapeutics shares in Q3 2023, an estimated $212K.
Bay Colony Advisors first reported a position in Intellia Therapeutics in Q4 2020 and held it in 11 quarters.
Bay Colony Advisors's Intellia Therapeutics position peaked at $737K in Q2 2021.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2023.

Based on Bay Colony Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.